{
  "repo": "research_papers",
  "file": "APOBEC3B_expression_in_breast_cancer_reflects_cellular_proliferation,_while_a_deletion_polymorphism_is_associated_with_immune_activation.pdf",
  "language": "research_paper",
  "content": "APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation David W. Cescona, b, c, d, 1, Benjamin Haibe-Kainsa, c, 1,  and Tak W. Maka, b, c, 2 aPrincess Margaret Cancer Centre, University Health Network,  M5G 2M9 Toronto,  Canada, bCampbell Family Institute for Breast Cancer Research,  M5G 2M9 Toronto,  Canada, cDepartment of Medical Biophysics,  University of Toronto,  M5G 1L7 Toronto,  Canada, anddDivision of Medical Oncology and Hematology,  Department of Medicine,  University of Toronto, M5G 2C4 Toronto,  Canada Contributed by Tak W. Mak,  January 12,  2015 (sent for review December 3, 2014, reviewed by Carlos Caldas) Genomic sequencing studies of breast and other cancers have identified patterns of mutations that have been attributed to the endogenous mutator activity of APOBEC3B (A3B), a member of the AID/APOBEC family of cytidine deaminases., A3B gene expression is increased in many cancers, but its upstream drivers remain undefined. Furthermore there exists a common germ-line deletion polymorphism ( A3Bdel), which has been associated with a paradox- ical increase in breast cancer risk., To examine causes and conse- quences of A3B expression and its constitutive absence in breast cancer, we analyzed two large clinically annotated genomic data- sets [The Cancer Genome Atlas (TCGA) and the Molecular Taxon- omy of Breast Cancer International Consortium (METABRIC)]., We confirmed that A3B expression is associated with aggressive clin- icopathologic characteristics and adverse outcomes and show that A3B expression is highly correlated with proliferative features (mi- tosis and cell cycle-related gene expression) in breast and 15 of 16 other solid tumor types., However breast cancers arising in homo- zygous A3Bdelindividuals with A3B absent did not differ in these features, indicating that A3B expression is a reflection rather than a direct cause of increased proliferation., Using gene set enrich- ment analysis (GSEA) we detected a pattern of immune activation inA3Bdelbreast cancers, which seems to be related to hypermu- tation arising in A3Bdelcarriers., Together these results provide an explanation for A3B overexpression and its prognostic effect, giv- ing context to additional study of this mutator as a cancer bio- marker or putative drug target., In addition although immune features of A3Bdelrequire additional study, these findings nomi- nate the A3Bdelpolymorphism as a potential predictor for cancer immunotherapy., cancer |mutagenesis |cellular proliferation The recent application of next generation sequencing tech- nologies to characterize the landscape of somatic alterations in solid tumors has yielded major insights into the genes and pathways operant in various cancers., In addition these studies have enabled the identification of distinct patterns of DNA base alterations that reflect underlying mutational processes (1 6)., One of the major discoveries of this effort was the high preva- lence of C >T transitions occurring in a preferred sequence motif (TCW, thymine/cytosine/adenine or thymine)., This pattern is consistent with the deaminase activity of the AID/APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypep- tide-like) family of enzymes,  and thus, its identification in- voked an endogenous mutator as a significant contributor to the somatic mutational burden across several cancer types (2 9)., Based on the sequence motifs expression levels, and subcellular localization of APOBEC family members, APOBEC3B (A3B) has been implicated as the likely mutator (6 8)., Analyses of cell line and tumor datasets have shown that A3B gene expression is up-regulated in malignant vs. normal tissues and epithelial cell lines and have shown correlations between A3B expression and the presence of certain somatic mutations, particularly in TP53 (7,  10) and PIK3CA (phosphatidylinositol-4, 5- bisphosphate 3-kinase, catalytic subunit alpha) (11)., Although the factors that cause up-regulation of A3B in cancer cell lines and tumors remain unknown these observations form the basis for a model where A3B expression contributes to the accumulation of somatic alterations during the process of carcinogenesis and sub- sequent evolution, and it has been suggested that inhibition of this activity could represent a strategy for cancer prevention or an ad- juvant to other therapies (7, 12)., A recent report that A3B ex- pression is associated with adverse outcomes in ER +breast cancer would be consistent with this hypothesis (13)., In contrast to these findings a germ-line deletion polymorphism inA3B (A3Bdel), which is present at allele frequencies approaching 100% in some populations (14), has been associated with an in- creased risk of breast cancer (15,  16)., This seemingly paradoxical finding suggests that if A3B is contributing cancer-causing muta- tions, it may also play some other function in restraining tumor development., A more recent analysis of the association between theA3Bdelpolymorphism and the APOBEC somatic mutational signature identified an increased mutational burden among A3Bdelcarriers, the etiology of which remains unknown (17)., We sought to address the biologic and clinical questions raised by these observations using two large clinically annotated breast cancer datasets with gene expression, copy number,  and mutational data (1, 18) with the chief aim of resolving the incongruence Significance Somatic mutagenesis is fundamental to the development and evolution of cancers., APOBEC3B (A3B) is a cellular deaminase which is overexpressed in cancers and believed to be an im- portant cause of cancer-associated mutations., The factors re- sponsible for A3B up-regulation are unknown. Interestingly a germ-line deletion polymorphism exists, such that a signifi- cant proportion of the global population does not express A3B protein., Using large human cancer datasets we show that A3B expression is strongly associated with cellular proliferation., Furthermore we identify a pattern of immune activation re- lated to hypermutation in tumors arising in A3B deletion car- riers suggesting that these patients could respond differently to immune-directed therapies., These results provide important context for the ongoing study of A3B as a therapeutic target or biomarker., Author contributions: D.W.C., B.H.-K., and T.W.M. designed research; D.W.C. and B.H.-K. performed research; D.W.C. and B.H.-K. analyzed data; and D.W.C., B.H.-K., and T.W.M. wrote the paper. Reviewers included: C.C., Cancer Research United Kingdom. The authors declare no conflict of interest. Freely available online through the PNAS open access option. 1D.W.C. and B.H.-K. contributed equally to this work. 2To whom correspondence should be addressed. Email: tmak@uhnres.utoronto.ca. This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1424869112/-/DCSupplemental . www.pnas.org/cgi/doi/10.1073/pnas.1424869112 PNAS |March 3, 2015 |vol. 112 |no. 9 |2841 2846 MEDICAL SCIENCES between gene expression and polymorphism associations. Taking advantage of the natural occurrence of A3B-null individuals (ho- mozygous for the A3Bdelallele), we assess the direction of causality forA3B gene expression associations and the biological con- sequences of the germ-line A3Bdelpolymorphism., These analyses have identified proliferation as the upstream feature associated with both increased A3B expression and adverse outcomes and revealed a distinct pattern of immune-related gene expression in tumors arising in A3Bdelcarriers compared with WT individuals., These findings will enable more focused study of A3B as a potential biomarker and suggest the possibility that the A3Bdel polymorphism could be used to identify patients with immune- activated tumors who may have differential benefit from cancer immunotherapies., Materials and Methods Datasets. We collected the two largest publicly available breast cancer datasets with both genomic and transcriptomic data, namely the Molecular Taxonomy of Breast Cancer International Conso rtium (METABRIC) (18) and The Cancer Genome Atlas (TCGA) (1)., For METAB RIC we downloaded the normalized gene expression profiles generated u sing the Illumina HT 12 IDATS platform and the clinical information from the European genome phenome archive (EGAS00000000083)., The mutation calls for TP53 generated by Sanger se- quencing of coding exons used were from the work by Silwal-Pandit et al., (10). A3Bdelpolymorphism genotypes were identified using Nexus Copy Number 7.0 software (BioDiscovery Inc.) to process Affymetrix-generated CEL files (EGAD00010000164)., Altogether we collected genomic,  transcriptomic,  and clinical information for 1, 992 breast cancer patients from METABRIC., For TCGA we downloaded the normalize d gene expression data generated using the Illumina RNA-seq platform and the clinical information from the cBioPortal (19) through the cgdsr R package (version 1.1., 30). Gene expression values were transformed as X=log2X+1 w h e r e Xrepresents the normalized fragments per kilobase transcript per million mapped reads values., The point mutation calls for TP53 PIK3CA , and other recurrently mutated genes were also downloaded from cBioPortal., A3Bdelpolymorphism genotype calls determined by analysis of next generation sequencing data as well as the hypermutation calls used were from the work by Nik-Zainal et al., (17). Altogether we col- lected genomic,  transcriptomic,  and clinical information for 1, 006 breast cancer patients from TCGA., For coexpression analysis in 59 breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) (20) and 16 other solid tumor types from TCGA, we used gene expression data (microarray for CCLE and RNA-seq for TCGA) and the coexpression function implemented on cBioPortal (19)., Molecular Subtyping. We used our robust subtype classification model SCMOD2 (21) implemented in the genefu R/Bioconductor package (version 1.16.0) to classify breast tumors into well-established molecular subtypes (21), basal (ER/HER2 ),  HER2 +,  and luminal (ER +/HER2 ), which can be further clas- sified into luminal B (ER +/HER2 highly proliferative tumors) and luminal A (ER+/HER2 lowly proliferative tumors)., Statistical Analysis. Association. We used Spearman s rank-based correlation coefficient (22) to esti- mate the strength and significance of the association between two continuous variables, such as gene expr ession., To estimate the significance of the association between a continuous variable and a bina ry variable, we used the Wilcoxon rank sum test (23), we used the Kruskal Wallis test (24) for discrete variables with more than two levels., Prognosis. We used the Cox proportional haza rds regression model (25) with disease-free survival to assess the prognostic value of gene expression as a con- tinuous variable., In particular, we used the D index (26) as a robust, unit-free estimate of the hazard ratio (HR). Significance of the D index was computed using the log-rank test (27). We estima ted the prognostic value of discrete var- iables such as gene expression, divided into binary or ternary groups based on quantiles or A3B allele calls using Kaplan Meier survival curves (28)., We used the log-rank test to test for differenc es between survival curves (27). Gene Ontology/Pathway Analysis. To identify functional clusters of genes coexpressed with A3B we performed Functional Annotation Clustering using DAVID (29) on the top 100 genes most strongly correlated with A3B expression in each dataset/tissue type., Gene Set Enrichment Analysis. To identify the pathways that are signifi- cantly enriched in genes associated with the A3Bdelpolymorphism, wecomputed the association of each gene with A3Bdelcalls using the fol- lowing logistic regression model, C=0+1X, w h e r e Cis the variable representing the A3Bdelcalls coded as 0 for homozygous and heterozygous deletions (A3Bdel/deland A3Bdel/WT, respectively) and 1 for WT ( A3BWT/WT)a s in ref., 17, and Xis the continuous expression value of each gene in the gene expression profiling platform. The strength and significance of association between each gene and A3Bdelcalls are given by the coefficient 1and its corresponding Pvalue (two-tailed Student ttest)., Based on the genome- wide ranking of genes based on the significance of their association with A3Bdelcalls, we used preranked gene set enrichment analysis (GSEA, version 22.1.0) (30) to identify gene sets and pathways significantly enriched in genes highly positively or negatively correlated to A3Bdelcalls., Gene sets were defined by all gene ontology (GO) (31) terms extracted from class c5 in MSigDB (32). We used a similar approach to identify gene sets enriched in genes as- sociated with the hypermutation calls defined by Nik-Zainal et al., (17). More specifically we used the same logistic regression model but replaced the A3Bdelcalls ( C) with the hypermutation status ( H)., To assess the effect of the A3Bdelpolymorphism beyond the hypermutation phenotype we updated the model to explicitly control for hypermutation when ranking the genes based on their association with A3Bdelcalls, C=0+1X+2H., As before the genes are ranked based on the significance of 1, and preranked GSEA is performed to identify the enriched pathways and gene sets., We performed the GSEA for A3Bdelin each of TCGA and the METABRIC datasets (separately) and for hypermutation status only in TCGA., In each case we performed the GSEAs for the global population of breast cancer patients as well as each subtype separately., Additional details are provided inSI Appendix ,Supplementary Methods . Reproducibility. To ensure full reproducibility this work complies with the guidelines proposed by Gentleman (33) in terms of the availability of the code and the reproducibility of results and figures., The procedure to prop- erly set up the software environment and run our analysis pipeline is pro- vided in SI Appendix ., All analyses were performed in both the METABRIC and TCGA datasets where corresponding data were available., Results from METABRIC which include more patients and have more complete clinical annotation, are shown in the figures for analyses involving clinicopathologic or survival end points., Results from TCGA are shown in the figures for coexpression and gene signature analyses because the RNA-seq data in this dataset provide a more quantitative measurement (34)., To show the high consistency of our results across datasets the corresponding figures using the second study are in- cluded in SI Appendix ., Results A3B Expression Correlates with Adverse Prognostic Features and Is Associated with Outcome in Breast Cancer., We evaluated the as- sociation between A3B gene expression [detected by microarray (METABRIC) or RNA-seq (TCGA)] and established clinico- pathologic features, focusing on the METABRIC dataset,  where clinical annotation is more complete., We found that presence of lymph node involvement histologic grade,  lack of ER expres- sion, and overexpression/amplification of HER2 are each asso- ciated with increased expression of A3B (Fig., 1). No significant correlation was observed between A3B expression and tumor size at diagnosis. Although A3B expression levels do vary by intrinsic subtype ( SI Appendix F i g .S 1 ), the association between A3B expression and tumor grade is present across all tumors as Fig., 1. A3B gene expression is associated with clinicopathologic fea- tures including lymph node involvement ( P=3.2104),  histologic grade ( P=1.41045), lack of ER expression ( P=4.81043),  and HER2 overexpression/amplification ( P=7.6105), in METABRIC breast can- cers., Pvalues are for the global dataset. 2842 |www.pnas.org/cgi/doi/10.1073/pnas.1424869112 Cescon et al. well as within each subtype (Fig. 1). Consistent with these observations in univariable analysis, A3B expression as a continuous variable is associated with recurrence [HR =1.54, 95% confidence interval (95% CI) =1.341.77,  P=1.2109], with its prognostic value being limited to the luminal tumor subtype (HR =1.60,  95% CI =1.341.93, P=4.1107)., To take into account the imprecision of HR estimates within sub- type we included an interaction term between A3B expression and luminal status in the Cox model., This interaction term was highly significant ( P=2.7105) suggesting that the observed difference of A3B prognostic value with respect to luminal status is statistically significant., This adverse prognosis associated with elevated A3B expression is similarly evident when patients are binarized into high and low A3B-expressing groups., Although this association holds across the entire METABRIC population it is driven by the luminal subgroups (Fig., 2). Several gene expression-based p rognostic signatures have been developed to predict breast cancer outcomes., We evaluated whether A3B expression is associated with scores calculated with these classifiers and observed strong correlation between A3B expression and several well-established signatures, including the Genomic Grade Index (35) (Fig., 3 and SI Appendix , Fig. S2 ), Chromosomal Instability (36), MammaPrint (also referred to GENE70) (37), and Oncotype DX (38). These associations were present in both datasets shared across subtypes, and either specific to or much stronger for A3B compared with other A3 family members., Proliferation has been identified as a common underlying feature driving these prognostic signatures (39)., We directly assessed the association between A3B expression and key proliferation-associated genes and observed strong correlation [for example, AURKA (aurora A kinase) (Fig., 4 and SI Appendix , Fig. S3 ),MKI67 , and CCNB1 ]. Indeed coexpression analysis in both METABRIC and TCGA identified strong enrichment of mitosis and cell cycle-related functional ontologies associated with A3B expression across all cancers and within subtypes ( SI Appendix , Table S1 )., We extended this analysis to 16 other solid tumor types using DAVID with RNA-seq gene expression data from TCGA and confirmed that A3B expression is strongly as- sociated with mitosis and cell cycle in 16 of 17 examined, with the exception lung squamous cell carcinoma ( SI Appendix ,  File S1 )., As in the breast cancer datasets the correlations between AURKA andA3B gene expression in these other tumor types provide support for the results of the GO analyses ( SI Appendix , Fig., S4 ). To further evaluate the prognostic importance of A3B ex- pression we performed multivariate analyses with a model in- corporating clinical features (age,  grade, tumor size,  nodal status,  and ER status) and proliferation-associated gene expression (AURKA )., When all of these features were considered A3B expression was no longer a significant predictor of outcome (all tumors,  HR =0.98, 95% CI =0.851.12,  P=0.74,  luminals,  HR=1.12,  95% CI =0.861.47,  P=0.39)., Borderline significancewas observed in luminal A and HER2 subgroups (luminal A HR=2.11, 95% CI =0.994.49,  P=0.053,  HER2,  HR =1.60,  95% CI =1.072.39,  P=0.02)., Together these analyses in two large independent breast cancer datasets affirm that A3B expression is associated with adverse prognostic features and outcomes in breast cancer and reveal a link to cellular proliferation., A3B Expression Is Increased in TP53 - but Not PIK3CA -Mutated Breast Cancers. Because A3B has been implicated as an endogenous mutator in breast and other cancers we evaluated the associa- tion between mutations in the most common recurrently altered genes in breast cancer ( TP53 andPIK3CA ) (1, 40) and A3B expression., As has been recently shown (10) we found that A3B expression is increased in tumors with TP53 mutations in both the METABRIC and TCGA datasets (Fig., 5 and SI Appendix , Fig. S5 A). For PIK3CA  however,  the presence of point muta- tions was,  instead, associated with lower A3B expression (Fig., 5) in breast cancers. Because the spectrum of base changes ascribed toA3B activity occurs in a specific sequence context we con- sidered the PIK3CA hotspot mutations separately, the E542K and E545K alterations conform to the A3B motif,  whereas H1047R does not (11)., Nevertheless each point mutation exhibited a similar pattern, where the presence of a PIK3CA alteration was associated with lower A3B expression (Fig., 5 and SI Appendix , Fig. S5 B). Systematic analysis of genes recurrently mutated in breast cancer (9) using TCGA breast dataset revealed no remarkable pattern of increased A3B expression in somati- cally mutated vs. unmutated tumors, although this analysis was0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 Fig., 2. High A3B gene expression is associated with recurrence after treatment for luminal breast cancer in METABRIC., Kaplan Meier plots are dichotomized by median A3B expression for all breast cancers (global) or within each intrinsic subtype., P<0.001 for global, luminals, luminal A, and luminal B. DFS, disease- free survival. 1.5 0.5 0.0 0.5 1.0 0.0 0.5 1.0 0.0 0.5 1.00.0 0.5 1.0 0.5 0.00.0 0.5 1.00 2 4 6 8 10 12 0 2 4 6 8 10 12 2 4 6 8 10 2 468 2468 1 0 02 4 6 8 101.0 1.5 0.5 1.0 1.5 0.5 1.00.5 1.0 Fig., 3. A3B gene expression correlates with the Genomic Grade Index (GGI) score in all breast cancers (global, =0.51,  P<11016) and within individual intrinsic subtypes (basal,  =0.23,  P=3.1103, H e r 2 , =0.33,  P=1.1104,  luminals,  =0.55,  P<11016, l u m i n a lA ,  =0.39,  P=1.41014,  luminal B, =0.53,  P<11016)i nT C G A ., Fig. 4. A3B gene expression correlates with expression of the proliferation- associated gene AURKA across all breast cancers (global, =0.46,  P<11016) and within individual intrinsic subtypes (basal,  =0.22,  P=3.8103, H e r 2 , = 0.28,  P=9.8104, l u m i n a l s ,  =0.50,  P<11016, l u m i n a lA ,  =0.31,  P=1.1 109, luminal B,  =0.45,  P=8.91016) in TCGA., Cescon et al. PNAS |March 3, 2015 |vol. 112 |no. 9 |2843 MEDICAL SCIENCES limited by low mutation frequency ( <10%) for all genes with the exceptions of TP53 , PIK3CA , CDH1 ,  and GATA3 ., Association Between A3B Expression and Proliferation Is Retained in Breast Cancer Cell Lines. To assess whether the observed associations between A3B expression and proliferati on are cell-autonomous, we further evaluated the relationship between A3B expression and proliferation in the CCLE breast cancer cell lines dataset., As in the METABRIC and TCGA breast tumor datasets coexpression analysis identified mitosis and cell cycle-related terms as the most strongly associated GOs ( SI Appendix , T a b l eS 2 )., Germ-Line A3BDeletion Polymorphism Is Associated with A3BExpression but Not Clinical Variables. To assess the causality of these A3B associations we evaluated associations between A3Bdeland these same factors,  reasoning that, if A3B expression contributes to the development of high-grade,  proliferative, and clinically aggres- sive cancers, the constitutional absence of A3B protein would result in an altered spectrum of tumor features., A3Bdelallele frequencies were determined for METABRIC and previously published values (17) were used for TCGA., As expected, A3B expression was highly associated with the A3Bdelgenotype (Fig. 6 andSI Appendix , Fig. S6 ). Importantly we did not observe re- ciprocal up-regulation of other A3 family members in the ab- sence of A3Bspecifically, expression of A3A (the 3 UTR of which is replaced by the A3B 3UTR in the polymorphic A3Bdelal- lele) was not increased in tumors from A3Bdelcarriers (Fig., 6 and SI Appendix , Fig. S6 ). In contrast to the associations observed between A3B expression and clinicopathologic features we observed no association be- tween the A3Bdelgerm-line polymorphism and tumor ER or HER2 status, lymph node involvement,  tumor grade,  intrinsic subtype distribution (Table 1), or somatic TP53 orPIK3CA mutation status ( SI Appendix ,  Table S3 )., Age at diagnosis was slightly lower in A3Bdelcarriers. As previously shown A3Bdelis asso- ciated with the presence of the hypermutation phenotype de- fined by Nik-Zainal et al., (17). Similarly we observed no association (either statistically sig- nificant or consistent trend) between A3Bdelstatus and expres- sion of individual proliferation-associated genes or prognostic signature scores (Fig., 6 and SI Appendix , Fig. S7 ). Finally we observed no association between the A3Bdelpolymorphism ge- notype and breast cancer outcomes (Fig., 7). Germ-Line A3B Deletion Polymorphism Is Associated with Expression of Immune-Related Genes in Breast Tumors., The surprising obser- vation that A3Bdelis not associated with any standard clinico- pathologic characteristics, despite the ascribed role for A3B asan endogenous mutator and the shown association between A3Bdeland breast cancer risk, prompted us to investigate the METABRIC and TCGA gene expression datasets to identify potential distinguishing features of tumors arising in A3Bdel carriers., To discover biological processes associated with A3Bdel, we applied GSEA (30) in METABRIC and TCGA. Consistent with our observatio ns above no association be- tween proliferation-associated processes and A3Bdelwas observed., Instead in each dataset, a striking association was identified be- tween A3Bdelstatus and enrichment of immune response-related gene sets [Table 2 shows the top-ranked gene set for METABRIC (immune response) and TCGA (cytokine binding)]., Immune Activation in A3BdelTumors Is Related to a Hypermutation Phenotype. Antitumor immune responses have been attributed to neoepitopes arising from somatic mutations in cancer cells (41), Fig., 5. A3B gene expression in TCGA breast ca ncers is increased in tumors with TP53 mutation (vs. WT) but decreased in tumors with any PIK3CA mutation or the E542K or E545K A3B motif mutations (vs. WT)., Similar associations are present across all tumors and within individual subtypes. Note that groups with less than three samples were omitted. MUT, mutation.A CDB Fig. 6. A3B expression is ( A) reduced in TCGA breast cancers from patients with germ-line A3Bdelpolymorphism ( B) without a reciprocal increase in A3A., The A3Bdelgenotype is not associated with ( C) expression of AURKA or (D) the Genomic Grade Index (GGI)., Similar patterns are present across all tumors and within intrinsic subtypes. Table 1. Association of A3Bdelpolymorphism with clinicopathologic features of breast cancers in the METABRIC and TCGA datasets Genotype A3Bdel/delA3Bdel/WTA3BWT/WTPvalue METABRIC All patients* 18 199 1, 771 Grades 1/2/3 1/7/9 22/71/95 147/695/851 0.7 Age (y) median (SD) 59.8 (10.7) 59.8 (12.8) 62.3 (13.0) 0.04 Size (cm) median (interquartile range)2.5 (1.0) 2.1 (1.4) 2.3 (1.3) 0.3 ER+ 83.3% 77.8% 77.3% 0.8 HER2+ 0.0% 18.8% 18.0% 0.4 Node+ 50.0% 46.2% 47.8% 0.9 Subtype 0.1 Luminal A/B 4/9 66/57 609/639 Basal 3 44 343 Her2 2 32 180 TCGA All patients* 13 86 597 Age (y) median (SD) 54 (12) 54 (12.4) 58 (13.3) 0.07 ER+ 69.2% 77.6% 78.9% 0.7 Node+ 62.5% 55.2% 49.8% 0.6 Subtype 0.54 Luminal A/B 3/3 25/34 160/240 Basal 2 12 95 Her2 5 12 83 Hypermutated30.8% 19.0% 10.7% 0.02 *For each data type, the total number of cases may differ because of missing or incomplete data., From the work by Nik-Zainal et al. (17). 2844 |www.pnas.org/cgi/doi/10.1073/pnas.1424869112 Cescon et al. and the A3Bdelpolymorphism has been associated with a hyper- mutation phenotype in breast cancers (17)., To assess whether hypermutation could be responsible for the A3Bdel-associated immune signature that we detected, we compared hypermutated with nonhypermutated breast cancers from TCGA (17) using GSEA., Across all tumors as well as within luminal and basal sub- types we identified a strong signal of immune activation in the hypermutated cancers reminiscent of the expression patterns in A3Bdelcancers (Table 2)., A3Bdelis associated with hypermutation status particularly in luminal tumors ( SI Appendix , F i g .S 8 )., To determine whether the A3Bdelpolymorphism contributes to im- mune activation independent of the hypermutation pheno- type, we constructed a GSEA linear model comparing tumors based on A3Bdelstatus corrected for hypermutation status., In this model the immune activation pattern was attenuated (Table 2), suggesting that hypermutation contributes to this phenomenon., Discussion Since the initial identification of a pattern of mutations fitting the activity of APOBEC3 enzymes in breast cancer sequencing data (3, 7,  8), numerous studies have gone on to identify a similar pattern of mutations across several human cancer types (2, 5,  6,  8,  42),  implicating A3B in somatic mutagenesis and by inference,  carcinogenesis., Despite the great interest that these results have attracted the cause of A3B up-regulation that is observed has remained enigmatic., Our results show that A3B expression is increased in highly proliferative states consistent with the in- creased expression in cancers v s. normal tissues (7, 43) and high- vs. low-grade tumors., Our analysis of A3B-null tumors (homozygous for the A3Bdelpolymorphism) however, revealed that the constitutive absence of A3B has no significant impact on the same clinicopathologic features., These data suggest that A3B expression is regulated in a cell cycle-dependent manner and gene expression profiling of cell cycle states supports this con- clusion (44)., An association with proliferation is also supported by the observation that APOBEC pattern mutations predomi- nate later in tumor evolution (42, 45)., Although increased A3B expression might result in accumulation of additional oncogenic mutations resulting in increased proliferation and a positive feedback loop, we show that A3B expression per se is not the primary cause of proliferative or adverse clinical features in breast cancer but rather, a consequence of these features., This finding has implications for the potential clinical use or appli- cation of strategies to inhibit A3B., Although these analyses do not directly address the in- creased risk of breast cancer development that has been as- sociated with the A3Bdelallele (15, 16),  we find no evidence of increased APOBEC3A-B hybrid mRNA expression in deletion carriers, which has been suggested as a potential cause of increased mutational burden and cancer risk in carriers (46)., However while performing our analyses, we did observe a remarkable association between expression of each of the APOBEC3 family members with the exception of A3B and IFN/inflammation-associated gene expression (STAT1 signature) ( SI Appendix , Fig., S10 ). In light of this finding it is conceivable that elevated expression of APOBEC3A occurs in A3Bdelcarriers during periods of inflammation and results in hit and run mu- tagenesis but is no longer detectable in the established tumors in the breast cancer datasets., We found no evidence of systematic differences in traditional clinicopathologic features subtype distributions,  or outcomes between breast cancers based on germ-line A3Bdelstatus, al- though the relatively low A3Bdelallele frequency (and consequent small numbers of A3Bdelhomozygous individuals) in these pre- dominantly Caucasian patient datasets is a limitation., Future analyses of other ethnic populations with higher A3Bdelallele frequency (14) will be important to confirm these findings., Nev- ertheless we have identified a reproducible pattern of increased immune response including cytokine and T-cell activation gene expression programs in tumors arising in A3Bdelcarriers., Al- though the nature and temporal development of the immune processes associated with the observed expression changes detected by GSEA are of great interest, this technique provides limited resolution to characterize the associated phenomena, and additional study is required., However given the canonical func- tion of APOBEC enzymes in the immune system (47,  48), several potential mechanisms for this observation could be considered arising from either tumor or immune cell intrinsic effects of the A3Bdelpolymorphism., The previously described association of A3Bdelwith a somatic hypermutation phenotype (17) and recent interest in the relationship between somatic mutational burden and antitumor immune response prompted us to examine the differences in gene expression profiles between the hypermutated and nonhypermutated breast cancers., Our analysis revealed to our knowledge, previously undescribed and marked immune ac- tivation in the hypermutated cancers., By controlling for the hypermutation status we observed that the original signal that we identified in A3Bdeltumors can be attributed, at least in part,  to increased mutational burden (or the process responsible for it)., Because hypermutation is likely a continuum but was binarized in these analyses (17) some or all of the residual immune- associated patterns in A3Bdeltumors may also be attributable to degrees of hypermutation., Lacking exome- or genome-level sequencing data in METABRIC confirmatory analyses in our second breast cancer dataset were not possible,  however, given the reproducible A3Bdel-associated immune gene expres- sion signatures, we believe that this phenomenon is likely generalizable., In light of the immune activation observed in A3Bdel- hypermutated tumors the increased breast cancer risk found inA3Bdelcarriers (15,  16) seems,  perhaps, counterintuitive., Although our analyses of established tumors are unable to0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 Fig., 7. Germ-line A3Bdelgenotype is not associated with recurrence after treatment for early breast cancer in METABRIC., Kaplan Meier plots show disease-free survival (DFS) by A3Bdelgenotype for all breast cancers (global) and by intrinsic subtypes., P>0.6 for all. Table 2. GSEA of A3Bdelvs.A3BWTand hypermutated vs. nonhypermutated breast cancers Comparison and gene set Normalized ES FDR qvalue METABRIC A3Bdelvs.A3BWT Immune response 3.19 <11016 Cytokine binding 2.68 <11016 TCGA breast A3Bdelvs.A3BWT Immune response 2.01 0.006 Cytokine binding 2.18 0.002 Hypermutated vs. not Immune response 2.81 <11016 Cytokine binding 2.30 <11016 A3Bdelvs.A3BWThypermutated model Immune response 1.77 0.096 Cytokine binding 1.93 0.068 ES, enrichment score,  FDR,  false discovery rate., Cescon et al. PNAS |March 3, 2015 |vol. 112 |no. 9 |2845 MEDICAL SCIENCES ascertain the presence or temporal development of the observed immune phenomena during tumorigenesis, the increased muta- tional rate/genomic instability presumably overrides the immune activation and results in tumor formation., We did not find any association between A3Bdeland breast cancer outcomes which one might expect in the setting of an activated immune response., However recent analyses of tumor-infiltrating lymphocytes in breast cancer have shown this pathologic measure of immune response to have important prognostic or predictive effects only in specific tumor subtypes or clinical contexts (49, 50)., Thus the lack of any detectable effect of A3Bdelon prognosis in this analysis is perhaps unsurprising, especially given the relationship with hypermutation that we identified., Notwithstanding the lack of prognostic effects of the A3Bdel polymorphism in patients treated with standard therapies in the METABRIC and TCGA cohorts, the r ecent and dramatic advances in the development of cancer immunotherapies (51) provide an emerging context where the immune effects that we have observed could be of clinical importance., Recent studies examining factors predictive of response to immune checkpoint inhibitors haveidentified associations between mutation- and immune-associ- ated features and treatment response (52 54), although they rely on complex tumor analyses,  including whole-exome sequencing., It is certainly plausible that the immune features associated with A3Bdelcancers (by way of the hypermutated phenotype) could influence response to immunotherapy-based treatment strate- gies., Genotyping for A3Bdel(which can be performed quickly and inexpensively from peripheral blood or tissue samples) could provide a simple selection or stratification factor to identify populations of interest for such treatments, and its exploration as a predictive biomarker is warranted., ACKNOWLEDGMENTS. We thank Dr. Samuel Aparicio [British Columbia Cancer Agency (BCCA)] for his advice and input. This study used data generated by The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium, we thank TCGA,  Cancer Research United Kingdom, and the BCCA for sharing these invaluable data with the scientific community., D.W.C. was supported by a Canadian Institutes of Health Research/Canadian Association of Medical Oncologists Fellowship., B.H.-K. was supported by the Gattuso-Slaight Personalized Cancer Medicine Fund at Prince ss Margaret Cancer Centre., 1. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61 70. 2. Alexandrov LB, et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain (2013) Signatures of mutational processes in human cancer., Nature 500(7463):415 421. 3. Nik-Zainal S, et al. Breast Cancer Working Group of the International Cancer Genome Consortium (2012) Mutational processes molding the genomes of 21 breast cancers., Cell149(5):979 993. 4. Stephens PJ, et al. Oslo Breast Cancer Consortium (OSBREAC) (2012) The landscape of cancer genes and mutational processes in breast cancer., Nature 486(7403):400 404. 5. Roberts SA, et al. (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45(9):970 976. 6. Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45(9):977 983. 7. Burns MB, et al. (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494(7437):366 370. 8. Taylor BJ, et al. (2013) DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis., eLife 2:e00534. 9. Lawrence MS, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214 218. 10. Silwal-Pandit L, et al. (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance., Clin Cancer Res 20(13):3569 3580. 11. Henderson S Chakravarthy A,  Su X,  Boshoff C , Fenton TR (2014) APOBEC-mediated cyto- sine deamination links PIK3CA helical domai n mutations to human papillomavirus-driven tumor development., Cell Rep 7(6):1833 1841. 12. Harris RS (2013) Cancer mutation signatures DNA damage mechanisms, and potential clinical implications., Genome Med 5(9):87. 13. Sieuwerts AM, et al. (2014) Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers., Horm Cancer 5(6):405 413. 14. Kidd JM Newman TL,  Tuzun E,  Kaul R, Eichler EE (2007) Population stratification of a common APOBEC gene deletion polymorphism., PLoS Genet 3(4):e63. 15. Long J, et al. (2013) A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 105(8):573 579. 16. Xuan D, et al. (2013) APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry., Carcinogenesis 34(10):2240 2243. 17. Nik-Zainal S, et al. (2014) Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer., Nat Genet 46(5):487 491. 18. Curtis C, et al. METABRIC Group (2012) The genomic and transcriptomic architecture of 2 000 breast tumours reveals novel subgroups., Nature 486(7403):346 352. 19. Gao J, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. 20. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive mod- elling of anticancer drug sensitivity., Nature 483(7391):603 607. 21. Haibe-Kains B, et al. (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104(4):311 325. 22. Spearman C (2010) The proof and measurement of association between two things. Int J Epidemiol 39(5):1137 1150. 23. Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics Bulletin 1(6):80 83. 24. Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. JA mS t a t Assoc 47(260):583 621. 25. Cox DR (1972) Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34(2):187 220. 26. Royston P, Sauerbrei W (2004) A new measure of prognostic separation in survival data. Stat Med 23(5):723 748. 27. Bland JM, Altman DG (2004) The logrank test. BMJ 328(7447):1073. 28. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457 481.29. Huang W Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources., Nat Protoc 4(1):44 57. 30. Subramanian A, et al. (2005) Gene set enrichment analysis A knowledge-based ap- proach for interpreting genome-wide expression profiles., Proc Natl Acad Sci USA 102(43):15545 15550. 31. Ashburner M, et al. ; The Gene Ontology Consortium (2000) Gene ontology: Tool for the unification of biology. Nat Genet 25(1):25 29. 32. Liberzon A, et al. (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27(12):1739 1740. 33. Gentleman R (2005) Reproducible research: A bioinformatics case study. Stat Appl Genet Mol Biol 4(2005):2. 34. Wang C, et al. (2014) The concordance betw een RNA-seq and microarray data depends on chemical treatment an d transcript abundance., Nat Biotechnol 32(9):926 932. 35. Sotiriou C, et al. (2006) Gene expression profiling in breast cancer Understanding the molecular basis of histologic grade to improve prognosis., J Natl Cancer Inst 98(4):262 272. 36. Carter SL Eklund AC,  Kohane IS,  Harris LN, Szallasi Z (2006) A signature of chromo- somal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers., Nat Genet 38(9):1043 1048. 37. van t Veer LJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530 536. 38. Paik S, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817 2826. 39. Desmedt C Sotiriou C (2006) Proliferation, The most prominent predictor of clinical outcome in breast cancer., Cell Cycle 5(19):2198 2202. 40. Lawrence MS, et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505(7484):495 501. 41. Chen DS, Mellman I (2013) Oncology meets immunology: The cancer-immunity cycle. Immunity 39(1):1 10. 42. de Bruin EC, et al. (2014) Spatial and temporal diversity in genomic instability pro- cesses defines lung cancer evolution., Science 346(6206):251 256. 43. Leonard B, et al. (2013) APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res 73(24):7222 7231. 44. Pena-Diaz J, et al. (2013) Transcription prof iling during the cell cycle shows that a subset of Polycomb-targeted genes is upregulated during DNA replication., Nucleic Acids Res 41(5): 2846 2856. 45. Zhang J, et al. (2014) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing., Science 346(6206):256 259. 46. Caval V Suspene R,  Shapira M,  Vartanian JP , Wain-Hobson S (2014) A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3 UTR enhances chromosomal DNA damage., Nat Commun 5(2014):5129. 47. Conticello SG Thomas CJF,  Petersen-Mahrt S K, Neuberger MS (2005) Evolution of the AID/ APOBEC family of polynucleotide ( deoxy)cytidine deaminases., Mol Biol Evol 22(2):367 377. 48. Moris A Murray S, Cardinaud S (2014) AID and APOBECs span the gap between in- nate and adaptive immunity., Front Microbiol 5:534. 49. Loi S, et al. (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer com- paring the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy, BIG 02-98., J Clin Oncol 31(7):860 867. 50. Loi S, et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer, Results from the FinHER trial., Ann Oncol 25(8):1544 1550. 51. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252 264. 52. Snyder A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189 2199. 53. Herbst RS, et al. (2014) Predictive corre lates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563 567. 54. Gubin MM, et al. (2014) Checkpoint blocka de cancer immunotherapy targets tumour- specific mutant antigens. Nature 515(7528):577 581. 2846 |www.pnas.org/cgi/doi/10.1073/pnas.1424869112 Cescon et al.",
  "qa_pairs": [
    {
      "question": "What is the main objective of the research in this paper?",
      "answer": "The main objective of the research in this paper is to investigate the expression of APOBEC3B (A3B) in breast cancer and its association with cellular proliferation and immune activation. The study aims to resolve the incongruence between A3B expression and a common germ-line deletion polymorphism (A3Bdel) that is paradoxically associated with increased breast cancer risk. By analyzing large clinically annotated genomic datasets, the researchers seek to understand the causes and consequences of A3B expression, its correlation with aggressive clinicopathologic characteristics, and the immune response patterns in tumors arising from individuals with the A3Bdel polymorphism. Ultimately, the findings aim to provide insights into A3B as a potential biomarker or therapeutic target in breast cancer and to explore the implications of the A3Bdel polymorphism for cancer immunotherapy."
    },
    {
      "question": "Can you summarize the abstract of the paper?",
      "answer": "The abstract of the paper discusses the role of APOBEC3B (A3B) in breast cancer, highlighting its expression as a marker of cellular proliferation and its association with aggressive cancer characteristics and poor outcomes. The study analyzes large genomic datasets (TCGA and METABRIC) to explore the implications of A3B expression and a common germ-line deletion polymorphism (A3Bdel) linked to increased breast cancer risk. The findings reveal that while A3B expression correlates with proliferation, its absence in A3Bdel individuals does not lead to significant differences in tumor features, suggesting that A3B expression is a consequence of increased proliferation rather than a direct cause. Additionally, immune activation patterns are identified in A3Bdel tumors, indicating potential implications for cancer immunotherapy. Overall, the study provides insights into A3B as a potential biomarker and therapeutic target in breast cancer."
    },
    {
      "question": "What are the softwares and computational tools that were used in this paper?",
      "answer": "The research paper utilized several software and computational tools for its analyses, including:\n\n1. **Nexus Copy Number 7.0** - This software was used to process Affymetrix-generated CEL files to identify A3Bdel polymorphism genotypes.\n\n2. **cBioPortal** - This platform was used to download normalized gene expression data and mutation calls for TP53, PIK3CA, and other recurrently mutated genes.\n\n3. **genefu R/Bioconductor package (version 1.16.0)** - This package was used for robust subtype classification of breast tumors.\n\n4. **DAVID** - This tool was employed for Functional Annotation Clustering to identify functional clusters of genes coexpressed with A3B.\n\n5. **Gene Set Enrichment Analysis (GSEA, version 22.1.0)** - This was used to identify pathways significantly enriched in genes associated with the A3Bdel polymorphism.\n\n6. **R programming language** - The analyses, including statistical tests and data transformations, were performed using R, specifically utilizing the cgdsr R package (version 1.1.30) for data retrieval.\n\nThese tools facilitated the analysis of genomic, transcriptomic, and clinical data from large breast cancer datasets, specifically TCGA and METABRIC."
    },
    {
      "question": "Describe the methodology used in the paper.",
      "answer": "The methodology used in the paper \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" involves several key components:\n\n1. **Data Collection**: The authors utilized two large, publicly available breast cancer datasets: The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). They collected genomic, transcriptomic, and clinical data for a total of 1,992 patients from METABRIC and 1,006 patients from TCGA.\n\n2. **Genomic and Transcriptomic Analysis**: The study involved downloading normalized gene expression profiles and mutation calls for key genes (such as TP53 and PIK3CA) from these datasets. The authors used various bioinformatics tools, including Nexus Copy Number software for processing Affymetrix-generated files and the cgdsr R package for accessing TCGA data.\n\n3. **Statistical Analysis**: The authors employed several statistical methods to analyze the data:\n   - **Correlation Analysis**: Spearman's rank-based correlation coefficient was used to assess the strength and significance of associations between continuous variables (e.g., gene expression levels).\n   - **Survival Analysis**: The Cox proportional hazards regression model was applied to evaluate the prognostic value of gene expression concerning disease-free survival, with the D index used as a measure of hazard ratios.\n   - **Gene Set Enrichment Analysis (GSEA)**: This was performed to identify pathways significantly enriched in genes associated with the A3B deletion polymorphism and hypermutation status.\n\n4. **Molecular Subtyping**: The authors classified breast tumors into established molecular subtypes using a robust subtype classification model (SCMOD2) implemented in the genefu R/Bioconductor package.\n\n5. **Coexpression Analysis**: Coexpression analysis was conducted using gene expression data from breast cancer cell lines and other solid tumor types to identify functional clusters of genes correlated with A3B expression.\n\n6. **Functional Annotation Clustering**: The authors performed functional annotation clustering using DAVID to identify gene clusters associated with A3B expression.\n\n7. **Reproducibility Measures**: The authors ensured reproducibility by following guidelines for data availability and providing a detailed procedure for setting up the software environment and running the analysis pipeline.\n\nOverall, the methodology combines extensive data analysis from large genomic datasets with robust statistical techniques to explore the relationships between APOBEC3B expression, cellular proliferation, and immune activation in breast cancer."
    },
    {
      "question": "What are the key findings of the paper?",
      "answer": "The key findings of the paper titled \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" can be summarized as follows:\n\n1. **Association of APOBEC3B Expression with Proliferation**: The study found that the expression of the APOBEC3B (A3B) gene is significantly associated with aggressive clinicopathologic characteristics and adverse outcomes in breast cancer. Specifically, A3B expression correlates strongly with features of cellular proliferation, such as mitosis and the expression of cell cycle-related genes.\n\n2. **Impact of A3B Deletion Polymorphism**: The research identified a common germ-line deletion polymorphism (A3Bdel) that is associated with an increased risk of breast cancer. Interestingly, breast cancers arising in individuals homozygous for the A3Bdel allele (where A3B is absent) did not exhibit the same aggressive features as those with A3B expression, suggesting that A3B expression is a reflection of cellular proliferation rather than a direct cause.\n\n3. **Immune Activation in A3Bdel Carriers**: Gene set enrichment analysis revealed a distinct pattern of immune activation in breast cancers from A3Bdel carriers. This immune activation appears to be related to a hypermutation phenotype associated with the A3Bdel polymorphism.\n\n4. **Prognostic Implications**: The findings provide context for further studies on A3B as a potential biomarker or therapeutic target in breast cancer. The A3Bdel polymorphism may serve as a predictor for responses to cancer immunotherapy, given its association with immune activation.\n\n5. **Lack of Association with Traditional Clinicopathologic Features**: The study found no significant associations between the A3Bdel polymorphism and traditional clinicopathologic features such as tumor grade, ER status, or HER2 status, indicating that the presence of A3Bdel does not alter these characteristics in established tumors.\n\nOverall, the research highlights the complex role of A3B in breast cancer, linking its expression to cellular proliferation while also suggesting that the A3Bdel polymorphism may influence immune responses in tumors."
    },
    {
      "question": "How was the data analyzed in the study?",
      "answer": "The data in the study was analyzed using several statistical and computational methods. The authors utilized two large, clinically annotated genomic datasets: The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). \n\n1. **Statistical Analysis**: \n   - **Correlation Analysis**: Spearman's rank-based correlation coefficient was used to estimate the strength and significance of associations between continuous variables, such as gene expression levels.\n   - **Comparative Tests**: The Wilcoxon rank sum test was employed to assess the significance of associations between continuous and binary variables, while the Kruskal-Wallis test was used for discrete variables with more than two levels.\n   - **Prognostic Analysis**: The Cox proportional hazards regression model was applied to evaluate the prognostic value of gene expression with respect to disease-free survival. The D index was used as a robust estimate of the hazard ratio, with significance assessed using the log-rank test.\n\n2. **Gene Set Enrichment Analysis (GSEA)**: \n   - GSEA was performed to identify pathways significantly enriched in genes associated with the A3B deletion polymorphism (A3Bdel). The analysis involved logistic regression models to assess the association of gene expression with A3Bdel status and to identify enriched gene sets and pathways.\n\n3. **Functional Annotation Clustering**: \n   - The authors used the DAVID bioinformatics resources to perform functional annotation clustering on the top genes correlated with A3B expression to identify functional clusters.\n\n4. **Coexpression Analysis**: \n   - Coexpression analysis was conducted using gene expression data from breast cancer cell lines and other solid tumor types to assess the relationship between A3B expression and proliferation-related genes.\n\n5. **Reproducibility Measures**: \n   - The study adhered to reproducibility guidelines, ensuring that the code and analysis pipeline were available for verification of results.\n\nOverall, the combination of these methods allowed the researchers to draw conclusions about the relationship between A3B expression, cellular proliferation, and immune activation in breast cancer."
    },
    {
      "question": "Was the data in the study pre-processed in anyway? If so how?",
      "answer": "Yes, the data in the study was pre-processed in several ways:\n\n1. **Data Collection**: The researchers collected two large publicly available breast cancer datasets, namely the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA). They downloaded normalized gene expression profiles and clinical information from these datasets.\n\n2. **Normalization**: For the METABRIC dataset, the gene expression profiles were generated using the Illumina HT 12 IDATS platform, and the researchers used the normalized data. For TCGA, the normalized gene expression data was generated using the Illumina RNA-seq platform.\n\n3. **Transformation**: The gene expression values in the TCGA dataset were transformed using the formula \\(X = \\log_2(X + 1)\\), where \\(X\\) represents the normalized fragments per kilobase of transcript per million mapped reads values. This transformation is a common practice to stabilize variance and make the data more normally distributed.\n\n4. **Genotype Identification**: The A3B deletion polymorphism (A3Bdel) genotypes were identified using Nexus Copy Number 7.0 software to process Affymetrix-generated CEL files.\n\n5. **Statistical Analysis**: Various statistical methods were employed to analyze the data, including Spearman's rank-based correlation coefficient for continuous variables, Wilcoxon rank sum test for continuous vs. binary variables, and Cox proportional hazards regression model for assessing prognostic values.\n\n6. **Gene Set Enrichment Analysis (GSEA)**: The researchers performed GSEA to identify pathways significantly enriched in genes associated with the A3Bdel polymorphism and hypermutation status.\n\nThese pre-processing steps were crucial for ensuring the data's quality and relevance for the study's objectives, allowing the researchers to draw meaningful conclusions about APOBEC3B expression and its implications in breast cancer."
    },
    {
      "question": "What conclusions were drawn in the paper?",
      "answer": "The conclusions drawn in the paper \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" can be summarized as follows:\n\n1. **Association of A3B Expression with Proliferation**: The study confirmed that the expression of APOBEC3B (A3B) is strongly associated with aggressive clinicopathologic characteristics and adverse outcomes in breast cancer. A3B expression correlates with features of cellular proliferation, such as mitosis and cell cycle-related gene expression, across breast cancer and other solid tumor types.\n\n2. **Reflection of Proliferation Rather than Cause**: The findings indicate that A3B expression is a reflection of increased cellular proliferation rather than a direct cause of it. This was evidenced by the lack of significant differences in proliferative features in breast cancers from individuals homozygous for the A3B deletion polymorphism (A3Bdel), where A3B is absent.\n\n3. **Immune Activation in A3Bdel Carriers**: The study identified a distinct pattern of immune activation in breast cancers arising in individuals with the A3Bdel polymorphism. This immune activation appears to be related to a hypermutation phenotype associated with A3Bdel carriers.\n\n4. **Implications for Cancer Biomarkers and Therapy**: The results provide important context for further studies on A3B as a potential biomarker or therapeutic target in cancer. Additionally, the A3Bdel polymorphism may serve as a predictor for responses to cancer immunotherapy, given its association with immune activation.\n\n5. **Need for Further Research**: The authors suggest that while the immune features associated with A3Bdel warrant further investigation, the findings highlight the complexity of the relationship between A3B expression, cellular proliferation, and immune response in the context of breast cancer.\n\nOverall, the study emphasizes the dual role of A3B in breast cancer, linking it to both proliferation and immune activation, and suggests potential clinical applications in cancer treatment and prognosis."
    },
    {
      "question": "Can you provide a summary of the literature review from the paper?",
      "answer": "The literature review in the paper \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" discusses the role of APOBEC3B (A3B) in cancer, particularly breast cancer. It highlights several key findings from genomic sequencing studies that have identified mutation patterns linked to the activity of A3B, a member of the AID/APOBEC family of cytidine deaminases. \n\nThe review notes that A3B expression is often upregulated in various cancers, including breast cancer, and is associated with aggressive tumor characteristics and poor clinical outcomes. However, the mechanisms driving this upregulation remain unclear. The literature also points out a common germ-line deletion polymorphism (A3Bdel) that paradoxically correlates with an increased risk of breast cancer, suggesting that A3B may have dual roles in cancer development.\n\nThe authors reference previous studies that have established a connection between A3B expression and specific somatic mutations, particularly in genes like TP53 and PIK3CA. They propose a model where A3B contributes to the accumulation of mutations during carcinogenesis, while also acknowledging that the absence of A3B in individuals with the A3Bdel polymorphism does not lead to significant differences in tumor characteristics, indicating that A3B expression may be a consequence of tumor proliferation rather than a direct cause.\n\nAdditionally, the review discusses the implications of A3B expression for cancer treatment, particularly in the context of immune activation observed in tumors from A3Bdel carriers. The authors suggest that these findings could inform future research on A3B as a potential biomarker or therapeutic target in cancer immunotherapy.\n\nOverall, the literature review synthesizes existing knowledge on A3B's role in cancer biology, emphasizing the need for further investigation into its mechanisms and implications for treatment strategies."
    },
    {
      "question": "What future research directions do the authors suggest in the paper?",
      "answer": "The authors suggest several future research directions in their paper:\n\n1. **Further Investigation of A3B as a Cancer Biomarker**: The findings indicate that A3B expression is associated with aggressive clinicopathologic characteristics and adverse outcomes in breast cancer. The authors propose that A3B could be studied further as a potential biomarker for cancer prognosis and treatment strategies.\n\n2. **Exploration of Immune Features Related to A3Bdel**: The study identifies a pattern of immune activation in tumors from individuals with the A3B deletion polymorphism (A3Bdel). The authors highlight the need for additional studies to understand the immune features associated with A3Bdel and how these may influence responses to cancer immunotherapy.\n\n3. **Genomic Studies in Diverse Populations**: The authors note that their findings regarding the A3Bdel polymorphism and its implications for breast cancer risk may benefit from further analysis in ethnic populations with higher frequencies of the A3Bdel allele. This could help confirm the observed associations and enhance understanding of the genetic factors influencing breast cancer risk.\n\n4. **Mechanistic Studies of A3B Function**: The authors suggest that the mechanisms underlying the regulation of A3B expression and its role in tumor biology warrant further investigation. Understanding these mechanisms could provide insights into the dual role of A3B in mutagenesis and immune response.\n\n5. **Clinical Implications of A3Bdel in Immunotherapy**: Given the association of A3Bdel with immune activation and hypermutation, the authors propose that future research could explore the potential of A3Bdel as a predictive biomarker for the efficacy of immunotherapy treatments in breast cancer patients.\n\nThese directions aim to deepen the understanding of A3B's role in breast cancer and its potential as a therapeutic target or biomarker."
    },
    {
      "question": "What statistical techniques were used in the paper?",
      "answer": "The paper utilized several statistical techniques to analyze the data related to APOBEC3B expression in breast cancer. The key statistical methods mentioned include:\n\n1. **Spearman's Rank-Based Correlation Coefficient**: This was used to estimate the strength and significance of the association between two continuous variables, such as gene expression levels.\n\n2. **Wilcoxon Rank Sum Test**: This test was employed to assess the significance of the association between a continuous variable and a binary variable.\n\n3. **Kruskal-Wallis Test**: This non-parametric method was used for comparing discrete variables with more than two levels.\n\n4. **Cox Proportional Hazards Regression Model**: This model was applied to evaluate the prognostic value of gene expression as a continuous variable, particularly in relation to disease-free survival.\n\n5. **D Index**: A robust, unit-free estimate of the hazard ratio (HR) was calculated, with significance assessed using the log-rank test.\n\n6. **Kaplan-Meier Survival Curves**: These were used to estimate the prognostic value of discrete variables, such as gene expression divided into binary or ternary groups.\n\n7. **Gene Set Enrichment Analysis (GSEA)**: This technique was employed to identify pathways significantly enriched in genes associated with the A3B deletion polymorphism and to analyze gene sets related to hypermutation status.\n\n8. **Logistic Regression Model**: This model was used to compute the association of each gene with A3B deletion calls, allowing for the estimation of the strength and significance of these associations.\n\nThese statistical techniques collectively facilitated the exploration of the relationships between APOBEC3B expression, clinical features, and genetic polymorphisms in breast cancer."
    },
    {
      "question": "Can you describe the experimental setup in the paper?",
      "answer": "The experimental setup described in the paper involves the analysis of two large, clinically annotated genomic datasets: The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). The researchers aimed to investigate the expression of the APOBEC3B (A3B) gene in breast cancer and its association with various clinical and biological features.\n\n1. **Datasets Used**: \n   - **METABRIC**: The researchers downloaded normalized gene expression profiles generated using the Illumina HT 12 IDATS platform, along with clinical information from the European Genome Phenome Archive. They collected genomic, transcriptomic, and clinical information for 1,992 breast cancer patients.\n   - **TCGA**: They obtained normalized gene expression data generated using the Illumina RNA-seq platform and clinical information from cBioPortal. This dataset included genomic, transcriptomic, and clinical information for 1,006 breast cancer patients.\n\n2. **Genomic and Transcriptomic Analysis**: \n   - The study involved analyzing gene expression levels of A3B and its correlation with clinicopathologic features such as lymph node involvement, histologic grade, and hormone receptor status (ER and HER2).\n   - The researchers also examined the presence of mutations in key genes (TP53 and PIK3CA) and their relationship with A3B expression.\n\n3. **Statistical Methods**: \n   - Various statistical analyses were performed, including Spearman's rank correlation, Wilcoxon rank sum tests, and Cox proportional hazards regression models to assess the prognostic value of A3B expression.\n   - Gene Set Enrichment Analysis (GSEA) was utilized to identify pathways significantly enriched in genes associated with the A3B deletion polymorphism (A3Bdel).\n\n4. **Coexpression Analysis**: \n   - The researchers conducted coexpression analyses in breast cancer cell lines and across 16 other solid tumor types to assess the relationship between A3B expression and proliferation-related gene expression.\n\n5. **Immune Activation Assessment**: \n   - The study also focused on identifying immune-related gene expression patterns in tumors from A3Bdel carriers compared to wild-type individuals, using GSEA to explore the association with hypermutation status.\n\nOverall, the experimental setup is characterized by the integration of large-scale genomic and transcriptomic data, statistical modeling, and bioinformatics analyses to elucidate the role of A3B in breast cancer proliferation and immune response."
    },
    {
      "question": "What are the implications of the research findings?",
      "answer": "The research findings of the paper titled \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" have several important implications:\n\n1. **Understanding of APOBEC3B Role**: The study clarifies that APOBEC3B (A3B) expression is not a direct cause of increased cellular proliferation in breast cancer but rather a reflection of it. This suggests that targeting A3B for therapeutic purposes may not yield the expected benefits if its expression is merely a byproduct of other underlying processes.\n\n2. **Prognostic Biomarker Potential**: The strong association between A3B expression and adverse clinicopathologic features indicates that A3B could serve as a prognostic biomarker for breast cancer. This could help in stratifying patients based on their risk and tailoring treatment strategies accordingly.\n\n3. **Implications for Immunotherapy**: The identification of immune activation patterns in tumors from individuals with the A3B deletion polymorphism (A3Bdel) suggests that these patients may respond differently to immune-directed therapies. This positions A3Bdel as a potential predictor for the effectiveness of cancer immunotherapy, highlighting the need for further studies to explore this relationship.\n\n4. **Insights into Tumor Biology**: The findings contribute to the understanding of the complex interplay between mutagenesis, immune response, and tumor proliferation. The association of A3Bdel with hypermutation and immune activation could inform future research on the mechanisms of tumorigenesis and the development of cancer therapies.\n\n5. **Future Research Directions**: The study opens avenues for further investigation into the biological processes associated with A3B and its deletion polymorphism. Understanding the mechanisms behind the immune activation in A3Bdel carriers could lead to novel therapeutic strategies that leverage the immune system to combat cancer.\n\n6. **Clinical Application**: The potential for A3Bdel to be used as a simple and cost-effective genetic marker for patient stratification in clinical settings is significant. It could facilitate the identification of patients who may benefit from specific immunotherapies based on their tumor's immune profile.\n\nIn summary, the research findings underscore the need for a nuanced understanding of A3B's role in breast cancer, with implications for prognosis, treatment strategies, and future research directions in cancer biology and immunotherapy."
    },
    {
      "question": "What are the limitations and delimitations mentioned in the paper?",
      "answer": "The research paper discusses several limitations and delimitations regarding the study of APOBEC3B expression and its implications in breast cancer. Here are the key points:\n\n### Limitations:\n1. **Low Allele Frequency**: The study notes that the A3Bdel allele frequency is relatively low in predominantly Caucasian patient datasets, which may limit the generalizability of the findings. This suggests that the results may not be applicable to populations with higher frequencies of the A3Bdel allele.\n\n2. **Lack of Exome or Genome-Level Sequencing**: The absence of comprehensive sequencing data in the METABRIC dataset limited the ability to perform confirmatory analyses in the second breast cancer dataset. This lack of detailed genomic information restricts the depth of the analysis regarding the mechanisms underlying the observed associations.\n\n3. **Imprecision in Prognostic Estimates**: The study acknowledges that the prognostic value of A3B expression was not significant when considering multiple clinical features, indicating that the relationship between A3B expression and clinical outcomes may not be straightforward.\n\n4. **Potential Residual Confounding**: While the study attempted to control for hypermutation status, the analysis may still be influenced by unmeasured confounding factors that could affect the observed immune activation patterns.\n\n### Delimitations:\n1. **Focus on Specific Datasets**: The study is limited to two large publicly available breast cancer datasets (METABRIC and TCGA), which may not encompass all possible variations and characteristics of breast cancer across different populations or subtypes.\n\n2. **Selection of Variables**: The analysis primarily focused on A3B expression and its correlation with specific clinicopathologic features, potentially overlooking other relevant factors that could influence breast cancer outcomes.\n\n3. **Binarization of Hypermutation Status**: The study categorized hypermutation status in a binary manner, which may oversimplify the complexity of mutational processes and their relationship with immune activation.\n\n4. **Generalizability of Findings**: The findings regarding immune activation in A3Bdel carriers may not be applicable to all breast cancer patients, particularly those outside the studied populations or those with different genetic backgrounds.\n\nThese limitations and delimitations highlight the need for further research to validate the findings across diverse populations and to explore the underlying mechanisms in greater detail."
    },
    {
      "question": "What recommendations do the authors make in the paper?",
      "answer": "The authors of the paper make several recommendations based on their findings regarding APOBEC3B (A3B) expression and the A3B deletion polymorphism (A3Bdel) in breast cancer:\n\n1. **Further Study of A3B as a Biomarker**: The authors suggest that A3B could be a potential biomarker for breast cancer due to its association with aggressive clinicopathologic characteristics and adverse outcomes. They recommend additional studies to explore A3B's role as a cancer biomarker.\n\n2. **Investigation of A3B as a Drug Target**: Given the findings that A3B expression is linked to cellular proliferation and adverse outcomes, the authors propose that A3B might be a putative drug target. They encourage research into strategies that could inhibit A3B activity as a means of cancer prevention or as an adjunct to existing therapies.\n\n3. **Examination of Immune Features in A3Bdel Carriers**: The authors highlight the need for further investigation into the immune activation patterns observed in breast cancers arising in individuals with the A3Bdel polymorphism. They suggest that these immune features could be relevant for understanding the response to cancer immunotherapy.\n\n4. **Potential Use of A3Bdel as a Predictor for Immunotherapy Response**: The authors nominate the A3Bdel polymorphism as a potential predictor for cancer immunotherapy, indicating that patients with this polymorphism may respond differently to immune-directed therapies.\n\n5. **Exploration of Ethnic Variability**: The authors note the relatively low frequency of the A3Bdel allele in the studied populations and recommend future analyses in other ethnic groups with higher A3Bdel allele frequencies to confirm their findings.\n\nOverall, the authors advocate for a deeper understanding of A3B's role in breast cancer, both as a biomarker and a therapeutic target, while also emphasizing the importance of immune response in the context of cancer treatment."
    },
    {
      "question": "Who funded the research in the paper?",
      "answer": "The research in the paper was funded by the following sources:\n\n1. David W. Cescon was supported by a Canadian Institutes of Health Research/Canadian Association of Medical Oncologists Fellowship.\n2. Benjamin Haibe-Kains was supported by the Gattuso-Slaight Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre.\n\nAdditionally, the study utilized data generated by The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium, with acknowledgments to TCGA, Cancer Research United Kingdom, and the British Columbia Cancer Agency for sharing these data."
    },
    {
      "question": "Is there any conflict of interest disclosed in the paper?",
      "answer": "Yes, the authors of the paper declare that there is no conflict of interest. This is explicitly stated in the paper's content where it mentions, \"The authors declare no conflict of interest.\""
    },
    {
      "question": "What ethical considerations are discussed in the paper?",
      "answer": "The paper discusses several ethical considerations related to the research findings on APOBEC3B (A3B) and its implications in breast cancer. Here are the key ethical considerations highlighted:\n\n1. **Potential for Misinterpretation of Genetic Risk**: The association of the A3B deletion polymorphism (A3Bdel) with increased breast cancer risk raises concerns about how genetic information might be interpreted by patients and healthcare providers. There is a risk that individuals may misunderstand the implications of carrying the A3Bdel polymorphism, potentially leading to anxiety or inappropriate health decisions.\n\n2. **Use of Genetic Testing**: The findings suggest that genotyping for the A3Bdel polymorphism could be a useful tool for identifying patients who may benefit from immunotherapy. However, ethical considerations arise regarding the accessibility of genetic testing, informed consent, and the implications of test results for patients and their families.\n\n3. **Implications for Treatment Decisions**: The research indicates that A3Bdel carriers may respond differently to immune-directed therapies. This raises ethical questions about how treatment decisions are made based on genetic information and the potential for unequal access to advanced therapies based on genetic profiles.\n\n4. **Patient Privacy and Data Sharing**: The study utilizes large publicly available datasets, which raises ethical concerns regarding patient privacy and the handling of sensitive genetic information. Ensuring that patient data is anonymized and used responsibly is crucial.\n\n5. **Equity in Research and Healthcare**: The paper notes that the A3Bdel allele frequency varies among populations, which could lead to disparities in research findings and healthcare access. Ethical considerations include ensuring that research benefits all populations and addressing potential biases in genetic research.\n\n6. **Future Research Directions**: The authors suggest that further studies are needed to explore the immune features associated with A3Bdel and their implications for cancer treatment. Ethical considerations in future research include the need for transparency, community engagement, and consideration of the potential societal impacts of the findings.\n\nOverall, the ethical considerations in the paper emphasize the importance of responsible communication of genetic research findings, equitable access to genetic testing and therapies, and the need for ongoing ethical reflection in cancer research."
    },
    {
      "question": "Which studies are most frequently cited in the paper?",
      "answer": "The most frequently cited studies in the paper \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" are as follows:\n\n1. **Cancer Genome Atlas Network (2012)** - Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.\n2. **Alexandrov LB et al. (2013)** - Signatures of mutational processes in human cancer. Nature 500(7463):415-421.\n3. **Nik-Zainal S et al. (2012)** - Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979-993.\n4. **Roberts SA et al. (2013)** - An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45(9):970-976.\n5. **Burns MB et al. (2013)** - Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45(9):977-983.\n6. **Silwal-Pandit L et al. (2014)** - TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20(13):3569-3580.\n7. **Henderson S et al. (2014)** - APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7(6):1833-1841.\n8. **Long J et al. (2013)** - A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 105(8):573-579.\n9. **Nik-Zainal S et al. (2014)** - Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 46(5):487-491.\n\nThese studies are referenced multiple times throughout the paper, indicating their significance in the context of the research presented."
    },
    {
      "question": "Can you explain the technical terms used in the paper?",
      "answer": "Certainly! Here are explanations for some of the technical terms used in the paper:\n\n1. **APOBEC3B (A3B)**: This is a member of the AID/APOBEC family of cytidine deaminases, which are enzymes that can convert cytidine to uridine in DNA and RNA. A3B is implicated in mutagenesis, particularly in cancer, as it can introduce mutations in the DNA of cells.\n\n2. **Germ-line deletion polymorphism (A3Bdel)**: This refers to a genetic variation where a segment of DNA (in this case, the A3B gene) is deleted in some individuals. This deletion can affect the expression of the A3B protein and has been associated with varying risks of developing breast cancer.\n\n3. **Gene Set Enrichment Analysis (GSEA)**: A computational method used to determine whether a predefined set of genes shows statistically significant differences in expression between two biological states (e.g., cancer vs. normal tissue). It helps identify biological pathways that are activated or suppressed in a given condition.\n\n4. **Somatic mutations**: These are alterations in DNA that occur after conception and can lead to cancer. They are not inherited but arise in non-germline tissues.\n\n5. **Clinico-pathologic characteristics**: These refer to the clinical and pathological features of a disease, such as tumor grade, stage, and the presence of specific biomarkers (e.g., hormone receptor status).\n\n6. **Hypermutation**: This term describes a condition where there is an unusually high rate of mutations within the DNA of a tumor. It can be a result of various factors, including the activity of mutator genes like A3B.\n\n7. **Prognostic value**: This refers to the ability of a particular factor (like gene expression) to predict the outcome of a disease, such as survival or recurrence rates in cancer patients.\n\n8. **Cox proportional hazards regression model**: A statistical method used to explore the relationship between the survival time of patients and one or more predictor variables. It is commonly used in medical research to assess the effect of treatments or other factors on survival.\n\n9. **Tumor-infiltrating lymphocytes (TILs)**: These are immune cells that have migrated into a tumor. Their presence is often associated with a better prognosis in various cancers, as they indicate an immune response against the tumor.\n\n10. **Molecular subtypes**: These are classifications of tumors based on their molecular characteristics, which can influence treatment decisions and prognostic outcomes. In breast cancer, common subtypes include luminal A, luminal B, HER2-positive, and triple-negative.\n\n11. **Next-generation sequencing (NGS)**: A modern DNA sequencing technology that allows for the rapid sequencing of large amounts of DNA, enabling comprehensive analysis of genetic variations in cancer.\n\n12. **Copy number variations (CNVs)**: These are alterations in the number of copies of a particular gene or genomic region, which can contribute to cancer development by affecting gene dosage.\n\nThese terms are essential for understanding the mechanisms of cancer biology discussed in the paper, particularly in relation to the role of A3B in breast cancer."
    },
    {
      "question": "What data sources were used in the paper, and are they accessible for further research?",
      "answer": "The research paper utilized two large publicly available datasets for its analysis: **The Cancer Genome Atlas (TCGA)** and the **Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)**. These datasets included genomic, transcriptomic, and clinical information for breast cancer patients, specifically focusing on gene expression, copy number, and mutation data.\n\nBoth TCGA and METABRIC datasets are accessible for further research. The authors mention that they downloaded data from these sources, which are publicly available, indicating that other researchers can access the same datasets for their studies. Additionally, the paper provides references to the specific data sources and methods used for data collection, which can guide other researchers in replicating or building upon this work. \n\nIn summary, the data sources used in the paper are TCGA and METABRIC, and they are accessible for further research."
    },
    {
      "question": "Can you summarize the research paper?",
      "answer": "The research paper titled \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" by David W. Cescon et al. investigates the role of the APOBEC3B (A3B) gene in breast cancer. A3B is a cytidine deaminase implicated in mutagenesis and is often overexpressed in various cancers, including breast cancer. The study aims to understand the factors driving A3B expression and the implications of a common germ-line deletion polymorphism (A3Bdel) associated with breast cancer risk.\n\nKey findings include:\n\n1. **Association with Proliferation**: The study confirms that A3B expression correlates with aggressive clinicopathologic features and poor outcomes in breast cancer. It is particularly linked to cellular proliferation, as evidenced by its correlation with mitosis and cell cycle-related gene expression across multiple cancer types.\n\n2. **A3Bdel Polymorphism**: The A3Bdel polymorphism, which results in the absence of A3B expression, paradoxically correlates with an increased risk of breast cancer. However, tumors from individuals with this deletion do not exhibit the same aggressive features associated with A3B expression, suggesting that A3B expression is a reflection of tumor proliferation rather than a direct cause.\n\n3. **Immune Activation**: Gene set enrichment analysis revealed a pattern of immune activation in tumors from A3Bdel carriers, indicating that these tumors may respond differently to immunotherapies. This immune activation is linked to a hypermutation phenotype observed in A3Bdel carriers.\n\n4. **Clinical Implications**: The findings suggest that while A3B expression is associated with poor prognosis due to its link to proliferation, the A3Bdel polymorphism may serve as a potential biomarker for identifying patients who could benefit from immune-directed therapies.\n\nOverall, the study provides insights into the dual role of A3B in breast cancer, highlighting its association with tumor proliferation and the immune response, and suggests avenues for further research into its potential as a therapeutic target or biomarker."
    },
    {
      "question": "What is the significance of this research in its field?",
      "answer": "The significance of the research presented in the paper \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" lies in its contributions to understanding the role of the APOBEC3B (A3B) enzyme in breast cancer and its potential implications for treatment strategies.\n\n1. **Understanding A3B's Role in Cancer**: The study elucidates the relationship between A3B expression and cellular proliferation in breast cancer. It demonstrates that while A3B is overexpressed in aggressive tumors and correlates with adverse clinical outcomes, its expression is a reflection of cellular proliferation rather than a direct cause of it. This distinction is crucial for interpreting the role of A3B in cancer biology and its potential as a therapeutic target.\n\n2. **Implications for Prognosis**: The findings suggest that A3B expression could serve as a prognostic biomarker, particularly in identifying patients with more aggressive forms of breast cancer. This could lead to more tailored treatment approaches based on A3B expression levels.\n\n3. **Insights into Genetic Polymorphisms**: The research also investigates the A3B deletion polymorphism (A3Bdel), which is paradoxically associated with an increased risk of breast cancer. The study identifies a pattern of immune activation in tumors from A3Bdel carriers, suggesting that these patients may respond differently to immune-directed therapies. This insight could inform the development of personalized immunotherapy strategies.\n\n4. **Broader Cancer Context**: By analyzing large genomic datasets, the research provides a broader context for A3B's role across various solid tumor types, reinforcing the enzyme's significance as a mutator in cancer evolution and its potential impact on treatment outcomes.\n\n5. **Future Research Directions**: The study opens avenues for further investigation into the mechanisms driving A3B expression and its interactions with immune responses in cancer. Understanding these dynamics could enhance the effectiveness of immunotherapies and contribute to the development of new therapeutic strategies.\n\nIn summary, this research is significant as it not only clarifies the role of A3B in breast cancer proliferation and prognosis but also highlights the potential for using genetic polymorphisms as predictive markers for immunotherapy responses, thereby advancing personalized medicine in oncology."
    },
    {
      "question": "How does this paper contribute to the existing body of knowledge?",
      "answer": "The paper titled \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" contributes to the existing body of knowledge in several significant ways:\n\n1. **Clarification of APOBEC3B's Role**: The study elucidates the relationship between APOBEC3B (A3B) expression and cellular proliferation in breast cancer. It demonstrates that while A3B expression is associated with aggressive tumor characteristics and poor outcomes, it is not a direct cause of increased proliferation but rather a reflection of it. This distinction is crucial for understanding the role of A3B in cancer biology.\n\n2. **Investigation of Germ-Line Deletion Polymorphism**: The paper explores the implications of a common germ-line deletion polymorphism (A3Bdel) associated with breast cancer risk. The findings suggest that tumors arising in individuals with this deletion exhibit a distinct immune activation pattern, which may have implications for cancer immunotherapy. This insight adds a new dimension to the understanding of genetic factors influencing cancer susceptibility and treatment response.\n\n3. **Use of Large Datasets**: By analyzing two large, clinically annotated genomic datasets (TCGA and METABRIC), the authors provide robust evidence for their conclusions. This approach enhances the reliability of their findings and allows for a comprehensive examination of the associations between A3B expression, tumor characteristics, and patient outcomes across different breast cancer subtypes.\n\n4. **Implications for Biomarkers and Therapeutics**: The results suggest that A3B could serve as a potential biomarker for cancer prognosis and a target for therapeutic strategies. The identification of immune activation in A3Bdel carriers also points to the possibility of using this polymorphism as a predictor for responses to immunotherapy, which is an emerging area of interest in cancer treatment.\n\n5. **Contribution to the Understanding of Mutational Processes**: The study contributes to the broader understanding of mutational processes in cancer, particularly the role of APOBEC enzymes in generating mutations. It highlights the complex interplay between genetic factors, immune responses, and tumor biology, which is essential for developing targeted therapies.\n\nOverall, this paper advances the understanding of APOBEC3B's role in breast cancer, the implications of genetic polymorphisms on tumor behavior, and the potential for personalized treatment strategies based on genetic profiling."
    },
    {
      "question": "Are there any novel techniques or approaches introduced in this paper?",
      "answer": "Yes, the paper introduces several novel techniques and approaches. Here are the key contributions:\n\n1. **Utilization of Large Genomic Datasets**: The authors analyzed two large, clinically annotated genomic datasets, The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). This approach allowed for a comprehensive examination of APOBEC3B (A3B) expression in relation to breast cancer characteristics and outcomes.\n\n2. **Gene Set Enrichment Analysis (GSEA)**: The authors employed GSEA to identify patterns of immune activation associated with the A3B deletion polymorphism (A3Bdel) in breast cancers. This technique helped to reveal the relationship between A3Bdel and immune-related gene expression.\n\n3. **Causality Assessment**: The study took advantage of the natural occurrence of A3B-null individuals (homozygous for the A3Bdel allele) to assess the direction of causality for A3B gene expression associations and the biological consequences of the A3Bdel polymorphism. This approach provided insights into how A3B expression correlates with tumor features and outcomes.\n\n4. **Multivariate Analysis**: The authors performed multivariate analyses incorporating clinical features and proliferation-associated gene expression to evaluate the prognostic importance of A3B expression. This method allowed them to determine the independent significance of A3B expression in relation to other clinical factors.\n\n5. **Comparative Analysis of Hypermutation Phenotypes**: The study compared hypermutated and non-hypermutated breast cancers to explore the immune activation patterns associated with the A3Bdel polymorphism. This comparative approach provided a deeper understanding of the relationship between mutational burden and immune response.\n\nOverall, these techniques and approaches contribute to a better understanding of the role of A3B in breast cancer and its potential implications for cancer immunotherapy."
    },
    {
      "question": "What are the potential real-world applications of this research?",
      "answer": "The research paper discusses the role of APOBEC3B (A3B) in breast cancer, particularly its expression levels and the implications of a germ-line deletion polymorphism (A3Bdel). Based on the findings presented in the paper, the potential real-world applications of this research include:\n\n1. **Cancer Biomarker Development**: The study suggests that A3B expression is associated with aggressive clinicopathologic characteristics and adverse outcomes in breast cancer. This indicates that A3B could serve as a biomarker for identifying patients at higher risk of poor prognosis, which could guide treatment decisions.\n\n2. **Target for Cancer Therapy**: Given the role of A3B in mutagenesis and its association with cancer progression, A3B may be a potential target for therapeutic interventions. Inhibiting A3B activity could represent a strategy for cancer prevention or as an adjunct to existing therapies, particularly in patients with high A3B expression.\n\n3. **Predictive Marker for Immunotherapy**: The research identifies a pattern of immune activation in tumors from A3Bdel carriers, suggesting that this polymorphism could be used to predict responses to cancer immunotherapy. Patients with the A3Bdel polymorphism may have tumors that respond differently to immune-directed therapies, making genotyping for A3Bdel a potential tool for patient stratification in immunotherapy trials.\n\n4. **Understanding Tumor Biology**: The findings contribute to the understanding of the biological mechanisms underlying breast cancer, particularly the relationship between mutagenesis, immune response, and tumor proliferation. This knowledge could inform the development of new therapeutic strategies and improve the management of breast cancer.\n\n5. **Population-Specific Risk Assessment**: Since the A3Bdel polymorphism has varying allele frequencies in different populations, this research could lead to population-specific assessments of breast cancer risk, helping to identify individuals who may benefit from enhanced screening or preventive measures based on their genetic background.\n\nIn summary, the research has significant implications for improving breast cancer diagnosis, treatment, and prevention strategies, particularly through the use of A3B as a biomarker and therapeutic target."
    },
    {
      "question": "How does the paper address potential biases in the research?",
      "answer": "The paper addresses potential biases in the research through several key strategies:\n\n1. **Use of Large, Clinically Annotated Datasets**: The authors analyzed two large datasets, The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), which provide extensive genomic and clinical data. This approach helps to mitigate biases that could arise from smaller or less comprehensive datasets.\n\n2. **Comparison of A3B Expression in Different Contexts**: The study distinguishes between A3B expression and the A3B deletion polymorphism (A3Bdel) by analyzing their associations with clinicopathologic features. By doing so, the authors clarify that A3B expression is a reflection of cellular proliferation rather than a direct cause, which helps to address potential confounding variables.\n\n3. **Multivariate Analysis**: The authors employed multivariate analyses that included various clinical features (such as age, tumor grade, and nodal status) alongside A3B expression. This statistical approach allows for the control of confounding factors, providing a clearer understanding of the relationship between A3B expression and clinical outcomes.\n\n4. **Reproducibility and Validation**: The study emphasizes reproducibility by ensuring that analyses were performed across both datasets (TCGA and METABRIC) and by including results from both to validate findings. This cross-validation helps to confirm that observed associations are not artifacts of a single dataset.\n\n5. **Control for Hypermutation Status**: The authors conducted analyses that controlled for hypermutation status when assessing the immune activation patterns associated with A3Bdel. This control helps to isolate the effects of the A3Bdel polymorphism from those of hypermutation, reducing potential biases in interpreting the results.\n\n6. **Acknowledgment of Limitations**: The authors recognize the limitations of their study, including the relatively low frequency of the A3Bdel allele in the predominantly Caucasian patient datasets. They suggest that future studies in populations with higher frequencies of the A3Bdel allele are necessary to confirm their findings, indicating an awareness of potential biases related to population genetics.\n\nBy employing these strategies, the paper aims to minimize biases and provide a more accurate interpretation of the relationship between APOBEC3B expression, the A3B deletion polymorphism, and breast cancer characteristics."
    },
    {
      "question": "What validation methods were used to ensure the reliability of the results?",
      "answer": "The validation methods used in the research paper \"APOBEC3B expression in breast cancer reflects cellular proliferation while a deletion polymorphism is associated with immune activation\" included several robust approaches to ensure the reliability of the results:\n\n1. **Use of Large Clinically Annotated Datasets**: The study analyzed two large datasets, The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), which provided extensive genomic, transcriptomic, and clinical data for a significant number of breast cancer patients (1,992 from METABRIC and 1,006 from TCGA). This large sample size enhances the statistical power and generalizability of the findings.\n\n2. **Statistical Analysis**: Various statistical methods were employed to assess associations and prognostic values:\n   - **Spearman's Rank Correlation Coefficient** was used to estimate the strength and significance of associations between continuous variables.\n   - **Wilcoxon Rank Sum Test** and **Kruskal-Wallis Test** were used for assessing associations between continuous and binary variables, and for discrete variables with more than two levels, respectively.\n   - **Cox Proportional Hazards Regression Model** was utilized to evaluate the prognostic value of gene expression concerning disease-free survival, providing hazard ratios and confidence intervals.\n\n3. **Gene Set Enrichment Analysis (GSEA)**: GSEA was performed to identify pathways significantly enriched in genes associated with the A3B deletion polymorphism and hypermutation status. This method helps in understanding the biological significance of gene expression patterns.\n\n4. **Reproducibility Measures**: The authors ensured reproducibility by complying with guidelines for data availability and providing detailed procedures for setting up the software environment and running the analysis pipeline. They also performed analyses in both datasets (METABRIC and TCGA) to confirm the consistency of results.\n\n5. **Multivariate Analyses**: The study included multivariate analyses that accounted for various clinical features and proliferation-associated gene expression, which helped to clarify the independent prognostic value of A3B expression.\n\n6. **Coexpression Analysis**: Coexpression analysis was conducted in breast cancer cell lines and across multiple solid tumor types to validate the association of A3B expression with proliferation-related features.\n\nThese validation methods collectively contribute to the reliability and robustness of the findings presented in the paper."
    },
    {
      "question": "Are there any contradictions between this paper's findings and previous research?",
      "answer": "The findings of the paper present some contradictions with previous research regarding the role of APOBEC3B (A3B) in breast cancer. \n\n1. **A3B Expression and Proliferation**: The paper indicates that A3B expression is associated with aggressive clinicopathologic characteristics and adverse outcomes in breast cancer, suggesting that A3B expression reflects cellular proliferation. This contrasts with earlier studies that implied A3B might directly contribute to tumorigenesis through its mutagenic activity. The authors clarify that while A3B expression correlates with proliferation, it is not the direct cause of increased proliferation; rather, it is a reflection of the proliferative state of the tumor.\n\n2. **A3Bdel Polymorphism and Cancer Risk**: The paper discusses the paradox of the A3B deletion polymorphism (A3Bdel), which has been associated with an increased risk of breast cancer. Previous studies suggested that A3B contributes to mutagenesis and thus cancer risk. However, the current study finds that tumors arising in A3Bdel carriers do not exhibit the same aggressive features associated with A3B expression, indicating that the absence of A3B does not lead to a different spectrum of tumor features. This raises questions about the mechanisms by which A3Bdel might increase cancer risk, suggesting that the relationship may not be straightforward and could involve other factors, such as immune activation.\n\n3. **Immune Activation**: The study identifies a pattern of immune activation in A3Bdel tumors, which is not typically associated with the mutagenic role of A3B. This finding contrasts with the traditional view that higher mutational burdens (often attributed to A3B activity) correlate with immune evasion rather than activation.\n\nIn summary, the paper challenges the notion that A3B expression is a direct driver of tumorigenesis and highlights the complexity of the relationship between A3B, its deletion polymorphism, and breast cancer risk, suggesting that further investigation is needed to reconcile these findings with previous research."
    }
  ]
}